+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
MALE
ID07005154

Evaluating ASP5541 Injection Versus Abiraterone Acetate Tablets with PrednisonePrednisolone for Advanced Prostate Cancer A Phase 2 Multi-Cohort Study

Led by Astellas Pharma Global Development, Inc. · Updated on 2026-09-03

218

Participants Needed

54

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating ASP5541, a new form of abiraterone acetate given by muscle injection, in men with advanced prostate cancer. The study compares ASP5541, with or without prednisoneprednisolone, to standard abiraterone acetate tablets plus prednisoneprednisolone. It aims to assess the safety and effectiveness of ASP5541 in men with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer who have not previously received androgen receptor pathway inhibitors. Participants are assigned to one of three groups men with metastatic castration-resistant prostate cancer receive either ASP5541 plus prednisoneprednisolone or abiraterone acetate plus prednisoneprednisolone men with metastatic hormone-sensitive prostate cancer receive either ASP5541 alone or abiraterone acetate with prednisoneprednisolone and Japanese men with either cancer type receive ASP5541 with prednisoneprednisolone. ASP5541 is administered by injection every 12 weeks, prednisoneprednisolone is taken orally once or twice daily depending on cancer type, and abiraterone acetate is taken daily as tablets. All participants continue standard androgen deprivation therapy. During the study, participants will have regular clinic visits for health monitoring and safety checks, with some checking blood pressure weekly at home. Imaging scans and laboratory tests will assess cancer progression and treatment effects. Researchers will measure outcomes such as prostate-specific antigen levels, safety events, testosterone suppression, and cancer progression. The study includes long-term follow-up for up to 84 months and aims to provide detailed information on the safety and efficacy of ASP5541 compared to existing treatments.

CONDITIONS

Brief Title

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Research Team

A

Astellas Pharma Global Development, Inc.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here